Comparative Pharmacology
Head-to-head clinical analysis: NYSTAFORM versus NYSTOP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NYSTAFORM versus NYSTOP.
NYSTAFORM vs NYSTOP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nystatin binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity and cause leakage of intracellular contents, leading to fungal cell death.
Nystatin binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular ions and cell death.
1 tablet (nystatin 100,000 units) orally three times daily after meals. Each tablet should be allowed to dissolve slowly in the mouth.
Apply a thin layer to affected area 2-3 times daily or as directed. Nystatin is not absorbed systemically; topical use only.
None Documented
None Documented
Plasma half-life is not measurable due to negligible systemic absorption. Topical or oral administration results in local action only; no systemic half-life is clinically relevant.
Not applicable for systemic pharmacokinetics due to minimal absorption; local half-life on mucosal surfaces is not defined. For intravenous administration (not approved), the terminal half-life is approximately 2-4 hours, but this route is not clinically used.
Nystatin is not absorbed from the gastrointestinal tract, intact skin, or mucous membranes. After oral administration, it is excreted almost entirely unchanged in feces (over 99%). Minimal renal excretion occurs (less than 1%).
Nystatin is not absorbed from the gastrointestinal tract or intact skin/mucous membranes; when administered topically or orally, it is excreted almost entirely in feces as unchanged drug (>99%). Less than 1% is excreted renally if ingested. No quantified biliary excretion reported.
Category C
Category C
Antifungal
Antifungal